Sanofi has detailed plans on how it will make significant investments in France to increase its vaccines research and production capacities and contribute in responding to future pandemic risks.
Sanofi will invest €610 million to create a new production site and research centre in France with both dedicated to vaccines.
“By investing in a new industrial site and a R&D centre, Sanofi positions France at the core of its strategy, aiming to make France a world-class centre of excellence in vaccine research and production,” said CEO Paul Hudson.
Sanofi will invest in vaccine production in France and create its Evolutive Vaccine Facility (EVF) in Neuville sur Saône. This state-of-the-art industrial site will utilise the latest innovative vaccine production technologies.
The project represents an investment of €490 million over a five-year period, and is expected to create 200 new jobs. Sanofi’s investment has been made possible thanks to the support and the close collaboration with French authorities over the last few months.
The building of this plant will enable Sanofi Pasteur – Sanofi’s global entity dedicated to vaccines – to be the first pharmaceutical manufacturer to benefit from such an industrial tool and to secure vaccine supplies in the event of new pandemics.
EVF is a new type of factory designed around a central unit housing several fully digital production modules that make it possible to produce three to four vaccines simultaneously, versus only one in current industrial sites. This modularity will make it possible to prioritise the production of a specific vaccine in a more timely manner based on public health issues.
Sanofi has also committed to investing €120 million to create a new R&D centre in France at the Sanofi Pasteur site in Marcy-l’Etoile to develop future vaccines.
This state-of-the-art digital facility will house highly specialised laboratories that will enable the development of vaccines against emerging diseases and pandemic risks.
The facility will become a world reference for pre-clinical research and pharmaceutical and clinical development. Sanofi expresses its gratitude to the Auvergne-Rhône-Alpes French region for its support in this project.